A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF THE LONG-TERM ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ALONE OR IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) VERSUS NSAIDS ALONE IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF THE LONG-TERM ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ALONE OR IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) VERSUS NSAIDS ALONE IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
The purpose of this study is to investigate the long-term analgesic efficacy and safety of tanezumab for patients with osteoarthritis (OA) of the knee or hip currently experiencing partial benefit from, and are tolerating, non-steroidal anti-inflammatory drug (NSAID) therapy.
This study was terminated on 28 October 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.
Inclusion Criteria:
Exclusion Criteria:
Pemkbroke Pines, Florida 33028, United States
St Louis, Missouri 63131, United States
Rock Hill, South Carolina 29732, United States
Bogota, Cundinamarca, Colombia
Bogota-Cundinamarca, Colombia
Secunderabad, Andhra Pradesh 500003, India
Guadalajara, Jalisco CP 44280, Mexico
Culiacan Sinaloa, CP 80230, Mexico
Leon Gto, C.P. 37000, Mexico
Torreon Coahuila, CP 27000, Mexico
Saint Petersburg, 194291, Russia
Parrowvalley, 7500, South Africa
Sabadell, Barcelona 08208, Spain
Santiago de Compostela, A Coruna, 15705, Spain